
  
    
      
        
        Postherpetic_NNP neuralgia_NN (_( PHN_NNP )_) is_VBZ a_DT chronically_RB painful_JJ condition_NN that_WDT is_VBZ a_DT complication_NN
        of_IN shingles_NNS (_( acute_JJ herpes_NNS zoster_NN )_) ,_, a_DT recurrence_NN of_IN the_DT varicella-zoster_JJ virus_NN ,_, which_WDT
        initially_RB causes_VBZ chickenpox_NN ._. Although_IN shingles_NNS usually_RB resolves_NNS within_IN a_DT month_NN ,_, some_DT people_NNS
        continue_VBP to_TO feel_VB the_DT pain_NN of_IN PHN_NNP long_RB after_IN the_DT rash_NN and_CC blisters_NNS heal_VB ,_, because_IN of_IN nerve_NN
        damage_NN (_( neuropathic_JJ pain_NN )_) caused_VBN by_IN the_DT shingles_NNS ._. Not_RB everyone_NN who_WP has_VBZ had_VBN shingles_NNS
        develops_VBZ PHN_NNP ,_, although_IN it_PRP is_VBZ a_DT common_JJ complication_NN of_IN shingles_NNS in_IN older_JJR adults_NNS ._.
        Despite_IN advances_NNS in_IN antiviral_JJ therapy_NN during_IN acute_JJ herpes_NNS zoster_NN and_CC the_DT more_RBR recent_JJ
        introduction_NN of_IN vaccination_NN against_IN varicella_NN zoster_NN ,_, PHN_NNP continues_VBZ to_TO be_VB a_DT significant_JJ
        clinical_JJ problem_NN ,_, with_IN 10_CD –_NN 20_CD %_NN of_IN patients_NNS developing_VBG persistent_JJ neuropathic_JJ pain_NN after_IN
        acute_JJ herpes_NNS zoster_NN reactivation_NN ._. The_DT nature_NN of_IN PHN_NNP pain_NN is_VBZ variable_NN ,_, which_WDT implies_VBZ that_IN a_DT
        variety_NN of_IN mechanisms_NNS might_MD be_VB operating_VBG ._. This_DT variability_NN has_VBZ led_VBN to_TO the_DT hypothesis_NNS that_WDT
        treatment_NN plans_NNS could_MD be_VB optimised_JJ for_IN individual_JJ patients_NNS on_IN the_DT basis_NN of_IN the_DT individual_JJ
        pattern_NN of_IN their_PRP$ symptoms_NNS or_CC the_DT underlying_VBG mechanism_NN of_IN the_DT pain_NN ._.
        However_RB ,_, the_DT current_JJ evidence_NN base_NN for_IN therapies_NNS in_IN PHN_NNP is_VBZ based_VBN on_IN clinical_JJ trials_NNS of_IN
        analgesics_NNS ,_, which_WDT have_VBP examined_VBN PHN_NNP as_IN a_DT single_JJ disease_NN entity_NN ._. Furthermore_RB ,_, there_EX is_VBZ
        little_JJ evidence_NN for_IN the_DT efficacy_NN of_IN drugs_NNS for_IN specific_JJ sets_NNS of_IN symptoms_NNS and_CC no_DT simple_JJ way_NN
        to_TO determine_VB which_WDT pain_NN mechanisms_NNS might_MD be_VB operating_VBG in_IN an_DT individual_JJ patient_NN ._.
        In_IN this_DT month_NN 's_POS 
        PLoS_NNP Medicine_NNP ,_, Andrew_NNP Rice_NNP and_CC colleagues_NNS reassessed_JJ the_DT evidence_NN base_NN
        by_IN doing_VBG a_DT systematic_JJ review_NN and_CC meta-analysis_JJ of_IN analgesic_JJ therapy_NN for_IN PHN_NNP ,_, which_WDT has_VBZ
        fundamentally_RB changed_VBN in_IN the_DT wake_NN of_IN several_JJ major_JJ new_JJ trials_NNS ._. The_DT authors_NNS searched_VBD the_DT
        literature_NN for_IN trials_NNS of_IN PHN_NNP and_CC retrieved_VBD 62_CD articles_NNS ,_, of_IN which_WDT 35_CD were_VBD kept_VBN for_IN final_JJ
        analysis_NN ._.
        Their_PRP$ analysis_NN confirmed_VBD several_JJ previous_JJ research_NN findings_NNS ,_, although_IN they_PRP cautioned_VBD
        that_IN the_DT meta-analytic_JJ study_NN design_NN of_IN collecting_VBG data_NNS from_IN a_DT range_NN of_IN trials_NNS had_VBD several_JJ
        inherent_JJ pitfalls_NNS ,_, and_CC it_PRP is_VBZ difficult_JJ to_TO directly_RB compare_VB treatments_NNS across_IN different_JJ
        trials_NNS ._.
        However_RB ,_, they_PRP found_VBD evidence_NN for_IN analgesic_JJ efficacy_NN in_IN established_VBN PHN_NNP for_IN orally_RB
        administered_VBN therapies_NNS ,_, such_JJ as_IN tricyclic_JJ antidepressants_NNS ,_, some_DT opioids_NNS ,_, gabapentin_NN ,_,
        tramadol_NN ,_, and_CC pregabalin_NN ._. Some_DT topically_RB administered_VBN therapies_NNS ,_, such_JJ as_IN lidocaine_NN and_CC
        capsaicin_NN ,_, were_VBD associated_VBN with_IN analgesic_JJ efficacy_NN in_IN selected_VBN patients_NNS ._. However_RB ,_, it_PRP
        appeared_VBD that_WDT therapies_NNS such_JJ as_IN oral_JJ administration_NN of_IN certain_JJ NMDA_NNP receptor_NN antagonists_NNS ,_,
        codeine_NN ,_, ibuprofen_NN ,_, lorazepam_NN ,_, 5_CD HT_NNP 1_CD receptor_NN agonists_NNS ,_, and_CC acyclovir_NN were_VBD not_RB efficacious_JJ
        in_IN PHN_NNP ._.
        Altogether_RB ,_, the_DT authors_NNS conclude_VBP that_IN the_DT evidence_NN base_NN supports_VBZ the_DT first-line_JJ use_NN of_IN a_DT
        tricyclic_JJ antidepressant_NN for_IN orally_RB administered_VBN treatment_NN of_IN PHN_NNP ,_, reserving_VBG the_DT
        gabapentinoids_NNS for_IN second-line_JJ use_NN ._. Topical_NNP treatments_NNS ,_, such_JJ as_IN lidocaine_NN or_CC capsaicin_NN ,_,
        should_MD be_VB considered_VBN as_IN first-line_JJ treatment_NN if_IN a_DT patient_NN falls_VBZ into_IN the_DT “ sensitised_JJ
        nociceptor_NN” as_IN opposed_VBN to_TO “ deafferentation_NN” sub-group_JJ of_IN PHN_NNP patients_NNS ._.
        The_DT role_NN of_IN intrathecal_NN steroid_NN is_VBZ still_RB not_RB clear_JJ :_: one_CD trial_NN indicated_VBD that_IN intrathecal_NN
        steroids_NNS were_VBD associated_VBN with_IN benefits_NNS in_IN patients_NNS with_IN PHN_NNP ,_, but_CC this_DT therapy_NN might_MD be_VB
        hazardous_JJ ,_, and_CC the_DT authors_NNS and_CC other_JJ researchers_NNS have_VBP concluded_VBN that_IN further_JJ high-quality_JJ
        trials_NNS of_IN this_DT therapy_NN are_VBP needed_VBN ._. The_DT authors_NNS found_VBD little_JJ evidence_NN regarding_VBG possible_JJ
        synergistic_JJ effects_NNS of_IN the_DT various_JJ treatments_NNS to_TO support_VB or_CC refute_VB the_DT concomitant_NN use_NN of_IN
        combinations_NNS of_IN drugs_NNS ._.
        They_PRP stressed_VBD that_IN any_DT treatment_NN plan_NN must_MD recognise_NN the_DT importance_NN of_IN the_DT
        biopsychosocial_NN model_NN of_IN chronic_JJ pain_NN and_CC that_IN any_DT pharmacologically_RB based_VBN management_NN of_IN
        PHN_NNP should_MD be_VB combined_VBN with_IN advice_NN on_IN and_CC management_NN of_IN psychological_JJ and_CC social_JJ
        aspects_NNS ._.
        Finally_RB ,_, as_IN there_EX is_VBZ no_DT single_JJ pathophysiology_NN that_IN underlies_NNS PHN_NNP ,_, they_PRP propose_VBP that_IN
        future_JJ studies_NNS should_MD use_VB quantitative_JJ sensory_JJ evaluation_NN to_TO clearly_RB categorise_NN subsets_NNS of_IN
        participants_NNS for_IN better_JJR interpretation_NN of_IN treatment_NN effects_NNS ._.
      
    
  
